Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ASO Visual Abstract: Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-Institutional Cohort.
Montgomery KB, Chandler McLeod M, DePalo DK, Dugan MM, Zager JS, Elleson KM, Sabel MS, Hieken TJ, Kottschade LA, Ollila DW, Pham V, Archer D, Berman RS, Lee AY, Cintolo-Gonzalez JA, McDonald HG, Winchester S, Burke EE, Rhodin KE, Beasley GM, Broman KK. Montgomery KB, et al. Among authors: kottschade la. Ann Surg Oncol. 2024 Dec 11. doi: 10.1245/s10434-024-16690-y. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39663327 No abstract available.
Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-institutional Cohort.
Montgomery KB, McLeod MC, DePalo DK, Dugan MM, Zager JS, Elleson KM, Sabel MS, Hieken TJ, Kottschade LA, Ollila DW, Pham V, Archer D, Berman RS, Lee AY, Cintolo-Gonzalez JA, McDonald HG, Winchester S, Burke EE, Rhodin KE, Beasley GM, Broman KK. Montgomery KB, et al. Among authors: kottschade la. Ann Surg Oncol. 2024 Nov 22. doi: 10.1245/s10434-024-16498-w. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39576454
Identification and Characterization of Immune Checkpoint Inhibitor-Induced Toxicities From Electronic Health Records Using Natural Language Processing.
Barman H, Venkateswaran S, Santo AD, Yoo U, Silvert E, Rao K, Raghunathan B, Kottschade LA, Block MS, Chandler GS, Zalis J, Wagner TE, Mohindra R. Barman H, et al. Among authors: kottschade la. JCO Clin Cancer Inform. 2024 Apr;8:e2300151. doi: 10.1200/CCI.23.00151. JCO Clin Cancer Inform. 2024. PMID: 38687915 Free PMC article.
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.
Kalogera E, Nevala WK, Finnes HD, Suman VJ, Schimke JM, Strand CA, Kottschade LA, Kudgus RA, Buhrow SA, Becher LR, Geng L, Glaser GE, Grudem ME, Jatoi A, Klampe CM, Kumar A, Langstraat CL, McWilliams RR, Wahner Hendrickson AE, Weroha SJ, Yan Y, Reid JM, Markovic SN, Block MS. Kalogera E, et al. Among authors: kottschade la. Clin Cancer Res. 2024 Jun 14;30(12):2623-2635. doi: 10.1158/1078-0432.CCR-23-3196. Clin Cancer Res. 2024. PMID: 38530846 Free PMC article. Clinical Trial.
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay E, Dronca RS, Yan Y, Markovic SN, Dimou A, Montane HN, Erskine CL, Piltin MA, Price DL, Khariwala SS, Hui J, Strand CA, Harrington SM, Suman VJ, Dong H, Block MS. Hieken TJ, et al. Among authors: kottschade la. Nat Commun. 2024 Feb 16;15(1):1430. doi: 10.1038/s41467-024-45798-8. Nat Commun. 2024. PMID: 38365756 Free PMC article. Clinical Trial.
Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma.
Sener U, Webb M, Breen WG, Neth BJ, Laack NN, Routman D, Brown PD, Mahajan A, Frechette K, Dudek AZ, Markovic SN, Block MS, McWilliams RR, Dimou A, Kottschade LA, Montane HN, Kizilbash SH, Campian JL. Sener U, et al. Among authors: kottschade la. J Immunother Precis Oncol. 2024 Feb 5;7(1):1-6. doi: 10.36401/JIPO-23-20. eCollection 2024 Feb. J Immunother Precis Oncol. 2024. PMID: 38327758 Free PMC article.
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
Smith KER, Peng KW, Pulido JS, Weisbrod AJ, Strand CA, Allred JB, Newsom AN, Zhang L, Packiriswamy N, Kottke T, Tonne JM, Moore M, Montane HN, Kottschade LA, McWilliams RR, Dudek AZ, Yan Y, Dimou A, Markovic SN, Federspiel MJ, Vile RG, Dronca RS, Block MS. Smith KER, et al. Among authors: kottschade la. Front Immunol. 2023 Oct 31;14:1279387. doi: 10.3389/fimmu.2023.1279387. eCollection 2023. Front Immunol. 2023. PMID: 38022659 Free PMC article. Clinical Trial.
66 results